Immuneering Corporation (IMRX)
4.82
-0.22 (4.37%)
Upcoming Events
Latest Headlines
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026 4:05 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Immuneering Corporation (IMRX)
August 27, 2026 7:08 AM - StreetInsider
Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
August 26, 2026 5:16 PM - StreetInsider
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026 5:16 PM - Globe NewsWire
H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy
August 6, 2026 6:06 AM - StreetInsider
Immuneering Corporation (IMRX) Reports In-Line Q2 EPS
August 5, 2026 9:09 AM - StreetInsider
Form 10-Q Immuneering Corp For: Jun 30
August 5, 2026 7:57 AM - SEC Filing
Form 8-K Immuneering Corp For: Aug 05
August 5, 2026 7:41 AM - SEC Filing
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G Immuneering Corp Filed by: BlackRock, Inc.
July 28, 2026 4:46 PM - SEC Filing
Immuneering publishes preclinical data on atebimetinib in Cancer Research
July 21, 2026 4:06 PM - StreetInsider
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
July 21, 2026 4:05 PM - StreetInsider
Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 17, 2026 4:29 PM - SEC Filing
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026 4:05 PM - StreetInsider
Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 16, 2026 4:11 PM - SEC Filing
Immuneering Corporation (IMRX) 7500 contracts of August 75 calls as share price up 6.2%
July 8, 2026 2:34 PM - StreetInsider
Cantor Fitzgerald Starts Immuneering Corporation (IMRX) at Overweight
July 8, 2026 6:06 AM - StreetInsider
Kalaris Therapeutics names Laurie Keating to its board
July 6, 2026 4:05 PM - StreetInsider
Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.
June 24, 2026 4:11 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew
June 16, 2026 4:15 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 15, 2026 4:12 PM - SEC Filing
Immuneering names Andrew Gengos as chief financial officer
June 15, 2026 7:30 AM - StreetInsider
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026 7:30 AM - StreetInsider
Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
June 11, 2026 5:38 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
June 11, 2026 5:33 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
June 11, 2026 5:30 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
June 11, 2026 5:26 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
June 11, 2026 5:23 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 11, 2026 5:16 PM - SEC Filing
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - Globe NewsWire
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - StreetInsider
Full Article List
